Investigators at the University of Pennsylvania School of Medicine suspect that lab-grown brain organoids developed from a patient’s own glioblastoma may hold the answers on how best to treat this aggressive and very deadly form of brain cancer. These findings are based on a study with a keen interest in organoids—rapidly becoming an integral part of the drug discovery process.
The findings titled “A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter-and Intra-tumoral Heterogeneity” were recently published in Cell and reveal how glioblastoma organoids may serve as effective models to expeditiously test personalized treatment strategies.
A Difficult and Deadly form of Brain Cancer
Glioblastoma multiforme (GBM) are difficult to treat mostly due to tumor heterogeneity. Although recent breakthroughs in treatment—from surgery, radiation and chemotherapy to more advanced personalized cellular therapies—can slow tumor growth down and help patients live longer a cure doesn’t exist.
Currently investigators don’t have a way to recapitulate a tumor to probe for complex characteristics as well as rapidly and qualitatively assess which pos...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).